Reactive Arthritis: Treatment Challenges and Future Perspectives.
Anti-TNF agents
Biodrugs
Interleukin-17
Interleukin-23
Reactive arthritis
Spondyloarthritis
Treatment
Journal
Current rheumatology reports
ISSN: 1534-6307
Titre abrégé: Curr Rheumatol Rep
Pays: United States
ID NLM: 100888970
Informations de publication
Date de publication:
26 05 2020
26 05 2020
Historique:
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
3
11
2021
Statut:
epublish
Résumé
Reactive arthritis is synovitis related to an infection away from the joint. The evolution is variable, frequently self-limited, but with the possible evolution to a prolonged form, generating functional incapacity and sequelae. New microbiological families have been incriminated and pathophysiological links have been clarified, highlighting the role of the mucous membranes (gut in particular), specific cell populations, and the production of pro-inflammatory cytokines. First-line pharmacological treatment is based on NSAIDs. In case of failure, synthetic and more recently biological DMARDs are indicated. Only open data are available for biological DMARDs but suggest good efficacy and safety. Reactive arthritis has not disappeared. The diagnosis must be mentioned by the clinic and history to allow the rapid introduction of an appropriate treatment.
Identifiants
pubmed: 32458153
doi: 10.1007/s11926-020-00904-9
pii: 10.1007/s11926-020-00904-9
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Antirheumatic Agents
0
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM